| Price | 1,654.60on 22-07-2019 at 16:30:00 |
|---|---|
| Change | 8.20 0.50% |
| Buy | 1,653.20 |
| Sell | 1,652.60 |
| Buy / Sell GSK Shares | |
| Last Trade: | Buy 502 at 1,653.437p |
| Day's Volume: | 4,672,640 |
| Last Close: | 1,646.40p |
| Open: | 1,646.40p |
| ISIN: | GB0009252882 |
| Day's Range | 1,639.20p - 1,662.00p |
| 52wk Range: | 1,408.80p - 1,672.00p |
| Market Capitalisation: | £81,837m |
| VWAP: | 1,653.751p |
| Shares in Issue: | 4,946m |
Recent Trades History Glaxosmithkline (GSK) |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 502 | 1,653.437 | Ordinary Delayed publication | 18:28:10 - 22-Jul-19 |
| Buy* | 72,019 | 1,654.715 | 17:50:42 - 22-Jul-19 | |
| Sell* | 1,439 | 1,651.994 | 17:42:32 - 22-Jul-19 | |
| Buy* | 21,371 | 1,656.771 | 17:40:38 - 22-Jul-19 | |
| Sell* | 614 | 1,651.598 | Ordinary Delayed publication | 17:40:33 - 22-Jul-19 |
| Sell* | 33,940 | 1,646.40 | 17:05:15 - 22-Jul-19 | |
| Buy* | 102 | 1,653.865 | 17:26:14 - 22-Jul-19 | |
| Sell* | 156,569 | 1,646.40 | 17:05:15 - 22-Jul-19 | |
| Buy* | 17,773 | 1,653.030 | 17:09:12 - 22-Jul-19 | |
| Buy* | 24,906 | 1,652.965 | 17:09:12 - 22-Jul-19 | |
Share Price History for Glaxosmithkline |
|||||
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| 19th Jul 2019 (Fri) | 1,654.00 | 1,662.40 | 1,639.00 | 1,649.80 | 7,480,572 |
| 18th Jul 2019 (Thu) | 1,650.00 | 1,660.00 | 1,645.20 | 1,660.60 | 5,335,749 |
| 17th Jul 2019 (Wed) | 1,666.00 | 1,669.80 | 1,653.20 | 1,665.00 | 6,530,554 |
| 16th Jul 2019 (Tue) | 1,646.60 | 1,672.00 | 1,645.40 | 1,638.60 | 10,511,603 |
| 15th Jul 2019 (Mon) | 1,618.00 | 1,643.40 | 1,614.40 | 1,623.80 | 5,853,570 |
| 12th Jul 2019 (Fri) | 1,633.20 | 1,634.20 | 1,615.00 | 1,632.40 | 6,155,355 |
| 11th Jul 2019 (Thu) | 1,649.00 | 1,658.00 | 1,627.80 | 1,643.20 | 9,830,351 |
| 10th Jul 2019 (Wed) | 1,637.00 | 1,646.00 | 1,628.20 | 1,640.20 | 5,667,811 |
| 9th Jul 2019 (Tue) | 1,622.20 | 1,643.40 | 1,622.20 | 1,628.00 | 6,270,497 |
| 8th Jul 2019 (Mon) | 1,629.80 | 1,631.80 | 1,619.80 | 1,636.60 | 9,833,159 |
| 5th Jul 2019 (Fri) | 1,636.80 | 1,645.80 | 1,628.40 | 1,639.00 | 5,096,604 |
| 4th Jul 2019 (Thu) | 1,637.80 | 1,645.20 | 1,635.80 | 1,641.20 | 3,277,522 |
| 3rd Jul 2019 (Wed) | 1,625.00 | 1,651.00 | 1,617.20 | 1,620.20 | 8,177,549 |
| 2nd Jul 2019 (Tue) | 1,600.00 | 1,620.20 | 1,591.60 | 1,590.40 | 9,072,995 |
| 1st Jul 2019 (Mon) | 1,594.80 | 1,602.60 | 1,581.60 | 1,576.60 | 6,180,692 |
| 28th Jun 2019 (Fri) | 1,581.80 | 1,583.60 | 1,570.40 | 1,582.00 | 5,385,995 |
| 27th Jun 2019 (Thu) | 1,587.80 | 1,587.80 | 1,564.80 | 1,587.20 | 5,234,774 |
| 26th Jun 2019 (Wed) | 1,601.40 | 1,604.40 | 1,581.20 | 1,605.60 | 8,233,723 |
| 25th Jun 2019 (Tue) | 1,587.40 | 1,608.60 | 1,581.00 | 1,593.00 | 5,377,881 |
| 24th Jun 2019 (Mon) | 1,577.60 | 1,597.80 | 1,572.40 | 1,576.40 | 10,206,599 |
GlaxoSmithKline, or 'GSK', is one of the world's leading pharmaceutical companies researching medicines and vacines alike for the World Health Organization's three priority diseases: HIV/AIDS, Malaria and Tuberculosis. With an estimated 7% of the world's pharmaceutical market under its wing, GSK remains one of the industry leaders globally but remains committed to the research and application of life changing and marketable drugs.
If investing in science seems a little confusing and unpredictable then perhaps some of GSK's over-the-counter and more recognisable products will help to convince; these include Gaviscon and Panadol, smoking control products such as Nicorette/Niquitin and nutritional healthcare drinks such as Lucozade, Ribena and Horlicks.
On 23rd January 2009, GSK announced that it had signed an agreement with UCB S.A to acquire its marketed product portfolio in certain parts of the Middle East, Africa, Latin America and Asia Pacific, for a cash consideration of some £484 million. President of Emerging Markets at GSK, Abbas Hussain, said that "This acquisition will strengthen and expand GSK's product portfolio in these countries, helping us to meet the needs of patients, particularly in the areas of epilepsy and respiratory." Under the agreement, GSK acquires several leading pharmaceutical brands and investors will be interested to know that the commercial operations and product distribution rights included represent approximately 3-4% of UCB's 2008 expected revenue of at least £3.09 billion. At the time of Mr Hussain speaking, share prices for GSK were steady at 1,226.00p with a "strong buy" recommendation from brokers.
News - Monday, July 22, 2019
The head of emerging markets at GlaxoSmithKline, Abbas Hussain, has issued a statement admitting that employees had acted in breach of Chinese Law and stating that the company will review the way it operated in China, amidst a corruption and bribery scandal....
News - Monday, July 22, 2019
The FTSE 100 climbed on Wednesday after insurers posted a positive performance, noting signs of a rebound in car premiums. Another major gainer was GlaxoSmithKline, who published better-than-expected results for the last quarter....
